Ikena Oncology Inc (IKNA)

Sector:
HEALTH CARE
Industry:
HEALTH CARE SERVICES
CEO:
Mark Manfredi
Employees:
50 NORTHERN AVE., BOSTON, MA 02210
857-343-8292

We are a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. Our principal corporate office is located at 645 Summer Street, Suite 101, Boston, MA.

Data derived from most recent annual or quarterly report
Market Cap 377.238 Million Shares Outstanding35.859 Million Avg 30-day Volume 82.65 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 37.61 / 9.63 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million

View recent insider trading info

Funds Holding IKNA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IKNA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KOEHLER MARIA

  • Director
26,838 2021-04-15 3

FORMELA JEAN FRANCOIS

  • Director
4,919,456 2021-03-30 1

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

ORBIMED GENESIS GP LLC

  • Director
5,586,311 2021-03-30 2

STAMPACCHIA OTELLO

  • Director
2,249,123 2021-03-30 1

BONITA DAVID P

  • Director
5,214,394 2021-03-30 2

ATLAS VENTURE FUND X, L.P.

ATLAS VENTURE ASSOCIATES X, L.P.

ATLAS VENTURE ASSOCIATES X, LLC

ATLAS VENTURE FUND XI, L.P.

ATLAS VENTURE ASSOCIATES XI, L.P.

ATLAS VENTURE ASSOCIATES XI, LLC

ATLAS VENTURE OPPORTUNITY FUND I, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.

ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC

  • 10% Owner
4,919,456 2021-03-30 1

SANTILLANA SERGIO L. CHIEF MEDICAL OFFICER

  • Officer
0 2021-03-25 1

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
IKENA ONCOLOGY INC IKNA 2021-10-22 22:15:03 UTC -1.1944 1.2644 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 21:45:03 UTC -1.1944 1.2644 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 21:15:03 UTC -1.1944 1.2644 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 20:45:03 UTC -1.1944 1.2644 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 20:15:03 UTC -1.1944 1.2644 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 19:45:03 UTC -1.1944 1.2644 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 19:15:03 UTC -1.1944 1.2644 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 18:45:03 UTC -1.1944 1.2644 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 18:15:03 UTC -1.1944 1.2644 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 17:45:03 UTC -1.1944 1.2644 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 17:15:03 UTC -1.1944 1.2644 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 16:45:03 UTC -1.1676 1.2376 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 16:15:04 UTC -1.1676 1.2376 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 15:45:03 UTC -1.1676 1.2376 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 15:15:03 UTC -1.1676 1.2376 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 14:45:03 UTC -1.1676 1.2376 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 14:15:03 UTC -1.1676 1.2376 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 13:45:03 UTC -1.1676 1.2376 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 13:15:03 UTC -1.1676 1.2376 20000
IKENA ONCOLOGY INC IKNA 2021-10-22 12:45:03 UTC -1.1676 1.2376 20000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments